XRAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DENTSPLY SIRONA Inc (XRAY) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is facing significant challenges, including weak financial performance, mixed analyst ratings, and lack of strong positive catalysts. While there is some stabilization in the dental market, the company's declining earnings and negative sentiment from analysts make it a less favorable option for long-term investment right now.
The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 60.257, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 12.287), which could act as a barrier to further upward movement.
Some evidence of dental market stabilization as noted by Barrington and UBS analysts. Pre-market price is up 1.08%, indicating short-term positive sentiment.
Weak financial performance in Q4 2025 with a 66.05% YoY drop in net income and a 66.20% YoY drop in EPS. Analysts have mixed to negative ratings, with Citi initiating a Sell rating and a $10 price target. Lack of significant insider or hedge fund activity. No recent news or congress trading data to act as a positive catalyst.
In Q4 2025, revenue increased by 6.19% YoY to $961M, but net income dropped significantly to -$146M (-66.05% YoY). EPS also declined by 66.20% YoY to -0.73, and gross margin fell to 46.1% (-8.31% YoY). These metrics indicate declining profitability despite revenue growth.
Analyst ratings are mixed to negative. Citi initiated a Sell rating with a $10 price target, citing weak macro conditions and competition eroding pricing power. Evercore ISI lowered its price target to $13 from $15. However, UBS and BofA are more optimistic, with Buy ratings and price targets of $16 and $17, respectively.
